BriLife, also known as IIBR-100, is a replication-competent recombinant VSV viral vectored COVID-19 vaccine candidate.^[1][2][3][4] It was developed by the Israel Institute for Biological Research (IIBR).^[1][5][6] The IIBR partnered with the US-based NRx Pharmaceuticals to complete clinical trials and commercialize the vaccine.^[7][8] A study conducted in hamsters suggested that one dose of the vaccine was safe and effective at protecting against COVID-19.^[9][3]

You can help expand this article with text translated from the corresponding article in Hebrew. (November 2021) Click [show] for important translation instructions. Machine translation, like DeepL or Google Translate, is a useful starting point for translations, but translators must revise errors as necessary and confirm that the translation is accurate, rather than simply copy-pasting machine-translated text into the English Wikipedia. Do not translate text that appears unreliable or low-quality. If possible, verify the text with references provided in the foreign-language article. You must provide copyright attribution in the edit summary accompanying your translation by providing an interlanguage link to the source of your translation. A model attribution edit summary is Content in this edit is translated from the existing Hebrew Wikipedia article at [[:he:BriLife]]; see its history for attribution. You should also add the template {{Translated|he|BriLife}} to the talk page. For more guidance, see Wikipedia:Translation.

Quick Facts Vaccine description, Target ...

BriLife

The former President of Israel, Reuven Rivlin, with the first vaccinator in Phase B of the IIBR-100 vaccine of the Israel Institute for Biological Research, at the Barzilai Medical Center.
Vaccine description
Target	SARS-CoV-2
Vaccine type	Viral vector
Clinical data
Other names	Brilife
Routes of administration	Intramuscular
ATC code	None

Close